119 filings
Page 3 of 6
8-K
jbqav5ovbuqauij
23 Aug 21
Other Events
4:44pm
8-K
xk89k0lc20064
12 Aug 21
Regulation FD Disclosure
8:03am
8-K
db7xeeul
9 Aug 21
Cara Therapeutics Reports Second Quarter 2021 Financial Results
4:10pm
8-K
bpqzejn8c1cyzmj7
4 Aug 21
Entry into a Material Definitive Agreement
12:00am
8-K
mh6u x2xhqf
7 Jun 21
Submission of Matters to a Vote of Security Holders
4:35pm
8-K
kfi73l627ajf4fc
10 May 21
Cara Therapeutics Reports First Quarter 2021 Financial Results
4:10pm
8-K
nh83i9jsk9g92ptpc2s8
29 Apr 21
Cara Therapeutics Announces Topline Results From
7:21am
8-K
w5mbw owrokk4nw
30 Mar 21
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
6:01am
8-K
ff61qpf gl7f2
8 Mar 21
Regulation FD Disclosure
8:38am
8-K
hnz jte8xz
25 Feb 21
Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
4:10pm
8-K
81ne 6xe4nops35r
28 Dec 20
Regulation FD Disclosure
8:35am
8-K
qq4apdy0kttl8ozmo6
9 Nov 20
Cara Therapeutics Reports Third Quarter 2020 Financial Results
4:10pm
8-K
0tky92bz
20 Oct 20
Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva™* to treat dialysis patients with pruritus
6:30am
8-K
z3jnsu 8m98nwylng
1 Oct 20
Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer
5:17pm
8-K/A
infqyb08zp2zxoib
11 Aug 20
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
f39y jhjw00
10 Aug 20
Cara Therapeutics Reports Second Quarter 2020 Financial Results
4:10pm
8-K
z00dxt1pspg5e6pzf5l
30 Jun 20
Departure of Directors or Certain Officers
7:18am
8-K
dap4h047jlym
17 Jun 20
Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with KARE Phase 2 Trial Design
7:11am
8-K
cn1g5z3a7s
5 Jun 20
Submission of Matters to a Vote of Security Holders
5:01pm
8-K
xlzg7ohj5fl0
11 May 20
Cara Therapeutics Reports First Quarter 2020 Financial Results
4:10pm